Worm M, MD1; Simpson EL, Thaçi D, et al. - The present study was conducted to evaluate the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. Between March 25, 2015, and October 18, 2016, the Study to Validate the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (LIBERTY AD SOLO-CONTINUE) was a randomized, double-blind, phase 3 clinical trial conducted at 185 sites in North America, Europe, Asia, and Japan. Researchers included a sum of 422 individuals (mean [SD] age, 38.2 [14.5] years; 227 [53.8%] male). The continued response over time was most consistently reported with dupilumab administered weekly or every 2 weeks. For both continuous and categorical endpoints, longer dosage intervals and placebo resulted in a diminution of response. There were no new safety signals. For long-term treatment, the approved regimen of 300 mg of dupilumab every 2 weeks is suggested.